Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
A Fabarius, A Leitner, A Hochhaus… - Blood, The Journal …, 2011 - ashpublications.org
The prognostic relevance of additional cytogenetic findings at diagnosis of chronic myeloid
leukemia (CML) is unclear. The impact of additional cytogenetic findings at diagnosis on …
leukemia (CML) is unclear. The impact of additional cytogenetic findings at diagnosis on …
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
A Fabarius, L Kalmanti, CT Dietz, M Lauseker… - Annals of …, 2015 - Springer
Major route additional cytogenetic aberrations (ACA) at diagnosis of chronic myeloid
leukaemia (CML) indicate an increased risk of progression and shorter survival. Since major …
leukaemia (CML) indicate an increased risk of progression and shorter survival. Since major …
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
B Hanfstein, MC Müller, R Hehlmann, P Erben… - Leukemia, 2012 - nature.com
In the face of competing first-line treatment options for CML, early prediction of prognosis on
imatinib is desirable to assure favorable survival or otherwise consider the use of a second …
imatinib is desirable to assure favorable survival or otherwise consider the use of a second …
[HTML][HTML] High-risk additional chromosomal abnormalities at low blast counts herald death by CML
R Hehlmann, A Voskanyan, M Lauseker, M Pfirrmann… - Leukemia, 2020 - nature.com
Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether
additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent …
additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent …
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Clonal cytogenetic evolution with additional chromosomal abnormalities (ACAs) in chronic
myelogenous leukemia (CML) is generally associated with decreased response to tyrosine …
myelogenous leukemia (CML) is generally associated with decreased response to tyrosine …
Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays
A Bennour, A Saad, H Sennana - Critical reviews in oncology/hematology, 2016 - Elsevier
Chronic myeloid leukemia (CML) is the prototype cytogenetic malignancy. Even before the
development of basic G-and R-banding techniques, CML was found to be associated with a …
development of basic G-and R-banding techniques, CML was found to be associated with a …
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete …
N Testoni, G Marzocchi, S Luatti… - Blood, The Journal …, 2009 - ashpublications.org
In chronic myeloid leukemia, different methods are available to monitor the response to
therapy: chromosome banding analysis (CBA), interphase fluorescence in situ hybridization …
therapy: chromosome banding analysis (CBA), interphase fluorescence in situ hybridization …
Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment
GC Issa, HM Kantarjian, GN Gonzalez… - Blood, The Journal …, 2017 - ashpublications.org
Clonal chromosomal abnormalities in Philadelphia chromosome-negative (CCA/Ph−)
metaphases emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are …
metaphases emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are …
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications
E Jabbour, JE Cortes, HM Kantarjian - Cancer, 2008 - Wiley Online Library
The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
How I treat newly diagnosed chronic phase CML
J Cortes, H Kantarjian - Blood, The Journal of the American …, 2012 - ashpublications.org
The progress made in the understanding of chronic myeloid leukemia (CML) since the
recognition of a common chromosomal abnormality to the introduction of ever more effective …
recognition of a common chromosomal abnormality to the introduction of ever more effective …